Atar D, Vandenbriele C, Agewall S, Gigante B, Goette A, Gorog DA, Holme PA, Krychtiuk KA, Rocca B, Siller-Matula JM, Valgimigli M, Rubboli A, Klamroth R (2025)
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy
Eur Heart J Cardiovasc Pharmacother, 11 (3), 275-289
DOI 10.1093/ehjcvp/pvaf006, PubMed 40145128

Måseide RJ, Berntorp E, Astermark J, Olsson A, Bruzelius M, Frisk T, Nummi V, Lassila R, Strandberg K, Tjønnfjord GE, Holme PA (2024)
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)
Res Pract Thromb Haemost, 8 (8), 102611
DOI 10.1016/j.rpth.2024.102611, PubMed 39807249

Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, Shah A, Holme PA, Poulsen LH, Meijer K, Simpson M, Mancuso ME (2024)
Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
Drugs R D, 25 (1), 89-98
DOI 10.1007/s40268-024-00494-2, PubMed 39702563